' Unprecedented' 3-Year Sustained Survival in SCLC With New Combo'Unprecedented' 3-Year Sustained Survival in SCLC With New Combo
The combination of durvalumab plus etoposide and cisplatin/carboplatin should now become the standard of care for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - October 7, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Small Cell Lung Cancer Highlights From IASLC 2021 Small Cell Lung Cancer Highlights From IASLC 2021
Dr Ramaswamy Govindan discusses key reports on small cell lung cancer from IASLC 2021, including data from the ATLANTIS trial and provocative findings from a single-cell atlas of SCLC patient tumors.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 4, 2021 Category: Consumer Health News Tags: Hematology-Oncology ReCAP Source Type: news

ATLANTIS Results: Lurbinectedin Plus Doxorubicin in SCLC ATLANTIS Results: Lurbinectedin Plus Doxorubicin in SCLC
Does improved safety and tolerability with lurbinectedin plus doxorubicin over standard of care in pretreated small cell lung cancer justify its use, despite seeing no survival benefit, ask experts.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 10, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Anlotinib appears to be cost effective as third- or further-line therapy for relapsed SCLC in China
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - September 1, 2021 Category: Drugs & Pharmacology Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Investor Update - August 3, 2021 Category: Pharmaceuticals Source Type: news

US FDA grants Priority Review to Roche ’s Tecentriq as adjuvant treatment for certain people with early non-small cell lung cancer
Basel, 3 August 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) has accepted the company ’s supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq® (atezolizumab) as adjuvant treatment following surgery and platinum-based chemotherapy for people with non-small cell lung cancer (NSCLC) whose tumours express PD-L1≥1%, as determined by an FDA-appro ved test. The FDA is reviewing the application under the Real-Time Oncology Review pilot programme, which aims to explore a more efficient review process to ensure safe and ef...
Source: Roche Media News - August 3, 2021 Category: Pharmaceuticals Source Type: news

Which Is More Aggressive, SCLC or NSCLC?
Title: Which Is More Aggressive, SCLC or NSCLC?Category: Diseases and ConditionsCreated: 7/30/2021 12:00:00 AMLast Editorial Review: 7/30/2021 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - July 30, 2021 Category: Cancer & Oncology Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

Genomic study points to new treatment approaches for advanced small-cell lung cancer
This study identified molecular changes in four subtypes of advanced SCLC. The findings could lead to the development of new targeted therapies for advanced SCLC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 26, 2021 Category: Cancer & Oncology Source Type: news

Drug testing approach uncovers effective combination for treating small cell lung cancer
(NIH/National Center for Advancing Translational Sciences (NCATS)) NIH researchers have identified and tested a drug combination that exploits a weakness in small cell lung cancer, an aggressive cancer. They targeted a vulnerability in cancer cell reproduction, increasing replication stress ¬ ¬ -- a hallmark of out-of-control cell growth in many cancers that damages DNA and forces cancer cells to constantly repair themselves. In a small trial, the drug duo shrank tumors in SCLC patients. The team's findings appear April 12 in Cancer Cell. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news

A new treatment for metastatic lung cancer
(University of Colorado Anschutz Medical Campus) A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could result in improved outcomes for patients with small cell lung cancer (SCLC) that has spread to the brain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2021 Category: Cancer & Oncology Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pembrolizumab SCLC Indication Withdrawn in US Pembrolizumab SCLC Indication Withdrawn in US
The small cell lung cancer (SCLC) indication had been granted an accelerated approval, but a subsequent confirmatory study showed no survival benefit.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 4, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Four Small Cell Lung Cancer Subtypes and Their Best Therapies Four Small Cell Lung Cancer Subtypes and Their Best Therapies
Researchers identified four SCLC subtypes and proposed that matching baseline tumor subtypes to SCLC therapy may enhance the depth and duration of response.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

ASCO Endorses Guidelines on Radiation Therapy for SCLC ASCO Endorses Guidelines on Radiation Therapy for SCLC
The American Society of Clinical Oncology (ASCO) has endorsed guidelines on radiation therapy for patients with small cell lung cancer (SCLC).Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Durvalumab not cost effective for first-line treatment of advanced SCLC
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - February 1, 2021 Category: Drugs & Pharmacology Source Type: news

Study defines small-cell lung cancer subtypes and distinct therapeutic vulnerabilities for each type
(University of Texas M. D. Anderson Cancer Center) Researchers from The University of Texas MD Anderson Cancer Center have developed the first comprehensive framework to classify small-cell lung cancer (SCLC) into four unique subtypes, based on gene expression, and have identified potential therapeutic targets for each type in a study published today in Cancer Cell. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 21, 2021 Category: International Medicine & Public Health Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Investor Update - October 29, 2020 Category: Pharmaceuticals Source Type: news

Roche ’s Tecentriq in combination with Avastin approved in China for people with the most common form of liver cancer
             Basel, 29 October 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) for the treatment of people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.“Today’s approval of Tecentriq in combination with Avastin for unresectable hepatocellular carcinoma means that people in China now have a cancer immunotherapy option which is changin...
Source: Roche Media News - October 29, 2020 Category: Pharmaceuticals Source Type: news

Oncotarget: NRXN1 as a novel potential target for small cell lung cancer
(Impact Journals LLC) The cover for issue 39 of Oncotarget features Figure 4, " Apoptosis assay of NRXN1-targeted ADC at IC50 dose calculated by growth inhibition curves, " by Yotsumoto, et al. which reported that the authors identified transmembrane proteins overexpressed specifically in SCLC with little or no expression in normal tissues and decided to focus on the cell adhesion molecule neurexin-1. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 30, 2020 Category: Cancer & Oncology Source Type: news

A Glimmer of Hope for Immunotherapy in SCLC? A Glimmer of Hope for Immunotherapy in SCLC?
While combination immunotherapy did not show a survival benefit after chemoradiotherapy in small cell lung cancer, longer follow-up and biomarker analysis may reveal some gains, suggests trial data.Medscape News UK (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - September 23, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Investor Update - September 17, 2020 Category: Pharmaceuticals Source Type: news

Roche to present a broad range of data across multiple cancer types at the ESMO Virtual Congress 2020
Basel, 17 September 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that results from a number of studies across its broad oncology portfolio will be presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, which will be held 19-21 September, 2020. Results include data from three phase III studies across the Tecentriq® (atezolizumab) triple-negative breast cancer (TNBC) programme. Central nervous system (CNS) efficacy data from integrated analyses of the pivotal phase II Rozlytrek® STARTRK-2, phase I STARTRK-1, and phase I ALKA-372-001 trials will be presented in addition to re...
Source: Roche Media News - September 17, 2020 Category: Pharmaceuticals Source Type: news

RethiNKing which immune cells are the best weapon against lung cancer
(Walter and Eliza Hall Institute) Immune cells called 'natural killer' (NK) cells could be a powerful weapon for fighting lung cancer, according to Melbourne researchers.Studying preclinical and patient samples of small cell lung cancer (SCLC), the Walter and Eliza Hall Institute team revealed that NK cells - but not T cells - are essential for slowing the aggressive spread of the cancer. 'Supercharging' the NK cells further boosted their cancer-fighting abilities. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - September 1, 2020 Category: Biology Source Type: news

Oncotarget: Correction of NSE concentration improves diagnostic accuracy in lung cancer
(Impact Journals LLC) Oncotarget Volume 11, Issue 27 published " Correction of the NSE concentration in hemolyzed serum samples improves its diagnostic accuracy in small-cell lung cancer " by Genet et al. which reported that this study aimed to develop a hemolysis correction equation and evaluate its role in small-cell lung cancer (SCLC) diagnostics. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 7, 2020 Category: Cancer & Oncology Source Type: news

Lurbinectedin (Zepzelca) Approved for Metastatic SCLC Lurbinectedin (Zepzelca) Approved for Metastatic SCLC
The FDA has granted accelerated approval for use of this new drug in metastatic small cell lung cancer (SCLC) that has progressed after or during treatment with platinum-based chemotherapy.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 16, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

Up-Front Stereotactic Radiosurgery an Option for SCLC Brain Mets Up-Front Stereotactic Radiosurgery an Option for SCLC Brain Mets
The trade-offs with first-line SRS without WBRT include a shorter time to new brain metastases without an apparent difference in overall survival, according to the FIRE-SCLC study.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - June 10, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Largest ever study of radiosurgery for brain metastases from small cell lung cancer
(University of Colorado Anschutz Medical Campus) The international First-line Radiosurgery for Small-Cell Lung Cancer (FIRE-SCLC) analysis led by University of Colorado Cancer Center researchers and published today in JAMA Oncology shows no overall survival benefit with whole-brain radiation therapy compared with radiosurgery in patients with small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 4, 2020 Category: Cancer & Oncology Source Type: news

Medicaid Not Associated with Improved Survival in Patients with SCLC
These findings suggest that there are significant outcome inequalities for patients with small cell lung cancer which are relevant to the policy debate on Medicaid expansion under the Affordable Care Act. (Source: CancerNetwork)
Source: CancerNetwork - April 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Use of Prophylactic Cranial Irradiation in Patients with Limited Stage SCLC
Researchers found that using prophylactic cranial irradiation after thoracic radiation in patients with limited-stage small cell lung cancer undergoing contemporary head imaging is not associated with a decrease in risk of developing new brain metastasis. (Source: CancerNetwork)
Source: CancerNetwork - April 23, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

Imfinzi (durvalumab) Approved in the US for Extensive-Stage Small Cell Lung Cancer
30 March 2020 -- AstraZeneca’s Imfinzi (durvalumab) has been approved in the US as a 1st-line treatment for adult patients with extensive-stage small cell lung cancer (ES-SCLC) in combination with standard-of-care (SoC)... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - March 30, 2020 Category: Drugs & Pharmacology Source Type: news

FDA OKs Durvalumab Combo for Extensive-Stage SCLC FDA OKs Durvalumab Combo for Extensive-Stage SCLC
The immunotherapy is now approved for use in patients with small cell lung cancer (SCLC); it was already approved for non-small cell lung cancer (NSCLC).FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - March 30, 2020 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA Approves Durvalumab Plus Standard of Care Chemo for Extensive-Stage SCLC
The FDA approved durvalumab (Imfinzi) as a first-line treatment for adult patients with extensive-stage small cell lung cancer in combination with standard-of-care chemotherapies, etoposide plus either carboplatin or cisplatin. (Source: CancerNetwork)
Source: CancerNetwork - March 30, 2020 Category: Cancer & Oncology Authors: Hannah Slater Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Media News - February 14, 2020 Category: Pharmaceuticals Source Type: news

China National Medical Products Administration grants approval of Roche ’s Tecentriq in combination with chemotherapy as first-line treatment of people with extensive-stage small cell lung cancer
Basel, 14 February 2020 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that China National Medical Products Administration (NMPA) has approved Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).“Small cell lung cancer is an area of major unmet need in China and one that has seen limited advances until now,” said Levi Garraway, M.D., Ph.D., Chief Medical Officer and Head of Global Product Development. “This approval makes Tecentriq the first cancer immunotherapy...
Source: Roche Investor Update - February 14, 2020 Category: Pharmaceuticals Source Type: news

New connections: Targeted treatment options for SCLC
Various studies reveal how we might effectively treat small cell lung cancer. (Source: Signal Transduction Knowledge Environment)
Source: Signal Transduction Knowledge Environment - February 10, 2020 Category: Science Authors: Ferrarelli, L. K. Tags: STKE Editors ' Choice Source Type: news

Revealed an alteration related to the loss of effectiveness of a treatment in lung cancer
(Josep Carreras Leukaemia Research Institute) Researchers from IJC reveal that non-smoking patients with lung cancer that have an alteration in RB1 and are treated with EGFR inhibitors, acquire resistance to treatment through the mechanism of histopathological transformation, either to non-small cell lung cancer (SCLC) or SLCL combined with a transformation to squamous cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 23, 2020 Category: Cancer & Oncology Source Type: news

Imfinzi granted FDA Priority Review for the treatment of patients with extensive-stage small cell lung cancer
AstraZeneca today announced that the US Food and Drug Administration (FDA) has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). (Source: World Pharma News)
Source: World Pharma News - November 29, 2019 Category: Pharmaceuticals Tags: Featured AstraZeneca Business and Industry Source Type: news

European Commission approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - September 6, 2019 Category: Pharmaceuticals Source Type: news

European Commission approves Roche ’s Tecentriq in combination with chemotherapy for the initial treatment of people with extensive-stage small cell lung cancer
Roche today announced that the European Commission has approved and granted marketing authorisation for Tecentriq ® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 6, 2019 Category: Pharmaceuticals Source Type: news

AbbVie Discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
MERU, a Phase 3 placebo-controlled trial evaluating Rova-T as a first-line maintenance therapy for advanced small-cell lung cancer (SCLC), demonstrated no survival benefit for patients receiving Rova-T at the interim analysis Independent Data Monitoring... Biopharmaceuticals, Oncology AbbVie, Rova-T, Rovalpituzumab Tesirine, small-cell lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 29, 2019 Category: Pharmaceuticals Source Type: news

Use of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer May Be Dropping Use of Prophylactic Cranial Irradiation for Extensive-Stage Small-Cell Lung Cancer May Be Dropping
Prophylactic cranial irradiation (PCI) for patients with extensive-stage small-cell lung cancer (ES-SCLC) appears to have become less common in the U.S., according to a new survey.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 24, 2019 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 26, 2019 Category: Pharmaceuticals Source Type: news

CHMP recommends EU approval of Roche ’s Tecentriq in combination with chemotherapy as an initial treatment of adults with extensive-stage small cell lung cancer
Roche today announced that the European Medicines Agency ’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Tecentriq® (atezolizumab) in combination with chemotherapy (carboplatin and etoposide) for the initial (first-line) treatment of adults with extensive-stage small cell lung cancer (ES-SCLC). (Source: Roche Media News)
Source: Roche Media News - July 26, 2019 Category: Pharmaceuticals Source Type: news

FDA Approves Keytruda (pembrolizumab) for the Treatment of Metastatic Small Cell Lung Cancer (SCLC)
KENILWORTH, N.J.--(BUSINESS WIRE)--June 18, 2019 Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda, Merck’s anti-PD-1 therapy, as... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - June 18, 2019 Category: Drugs & Pharmacology Source Type: news

Dr. Farago on Trilaciclib for Myelosuppression in Previously Treated Extensive-Stage SCLC
Cancer Network spoke with Anna F. Farago, MD, of Massachusetts General Hospital, about the effect of trilaciclib on myelosuppression in patients with previously treated extensive-stage small-cell lung cancer receiving topotecan. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2019 Category: Cancer & Oncology Authors: Anna F. Farago, MD, PhD Source Type: news